Characteristics of patients with relapses and rescue treatments
| Patients, n (%) | 9 (31) |
| Median time to recurrence (from irradiation) (mo): median (IQR, 25-75] | 8.7 [4-11.5] |
| Pattern of recurrence, n (%) | |
| Unifocal | 4 (44) |
| Multifocal | 5 (56) |
| Site of recurrence, n (%) | |
| Initial | 1 (12) |
| Distant | 8 (88) |
| Second-line chemotherapy, n | |
| R-ICE | 5 |
| Other (IVA, ibrutinib, R-lenalidomide, R-MBVP) | 4 |
| IC-ASCT, n (%) | 5 (55) |
| At first recurrence | 2 |
| Later | 3 |
| Patients, n (%) | 9 (31) |
| Median time to recurrence (from irradiation) (mo): median (IQR, 25-75] | 8.7 [4-11.5] |
| Pattern of recurrence, n (%) | |
| Unifocal | 4 (44) |
| Multifocal | 5 (56) |
| Site of recurrence, n (%) | |
| Initial | 1 (12) |
| Distant | 8 (88) |
| Second-line chemotherapy, n | |
| R-ICE | 5 |
| Other (IVA, ibrutinib, R-lenalidomide, R-MBVP) | 4 |
| IC-ASCT, n (%) | 5 (55) |
| At first recurrence | 2 |
| Later | 3 |
IVA, ifosfamide, vincristine, actinomycin; R-ICE, rituximab, ifosfamide, carboplatin, etoposide.